首页> 外文OA文献 >Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

【2h】

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

机译：胰岛素Aspart BioSimilar SAR341402对糖尿病患者的疗效和安全性与糖尿病患者的胰岛素胰岛素Aspart，随着胰岛素狼犬组合的多次注射治疗26周：随机开放标签试验（Gemelli 1）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Satish K. Garg; Karin Wernicke-Panten; Marek Wardecki; Daniel Kramer; Francois Delalande; Edward Franek; Karita Sadeharju; Travis Monchamp; Bhaswati Mukherjee; Viral N. Shah;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1) [J] . Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki, Diabetes technology & therapeutics . 2020,第2期

机译：胰岛素Aspart BioSimilar SAR341402对糖尿病患者胰岛素胰岛素Aspart的疗效和安全性与胰岛素胰岛素组合的糖尿病患者治疗26周：随机开放标签试验（Gemelli 1）
2. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial [J] . Diabetes technology & therapeutics . 2020,第7期

机译：胰岛素Aspart的安全性，免疫原性和血糖控制BioSimilar SAR341402对糖尿病患者的胰岛素胰岛素Aspart也使用胰岛素狼犬：12个月的Gemelli 1试验结果
3. Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin [J] . Viral N. Shah, Edward Franek, Karin Wernicke-Panten, Diabetes therapy . 2021,第2期

机译：胰岛素Aspart BioSimilar SAR341402的功效，安全性和免疫原性与糖尿病（Gemelli 1）的成人发起胰岛素Aspart相比：通过现有的膳食胰岛素的亚组分析
4. Reinforcement Learning-Based Adaptive Insulin Advisor for Individuals with Type 1 Diabetes Patients under Multiple Daily Injections Therapy^* [C] . Qingnan Sun, Marko V. Jankovic, Stavroula G. Mougiakakou Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2019

机译：基于强化学习的1型糖尿病患者每日多次注射疗法的自适应胰岛素顾问^*
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Safety Immunogenicity and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial [O] . Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki, -1

机译：门冬胰岛素的安全性免疫原性和血糖控制生物仿制药SAR341402与始发者门冬胰岛素在也使用胰岛素甘精胰岛素的糖尿病患者中的关系：GEMELLI 1试验的12个月结果
7. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial [O] . Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki, 2020

机译：安全性，免疫原性和胰岛素的血糖控制生物仿制性SAR341402与糖尿病患者的胰岛素胰岛素Aspart也使用胰岛素狼犬：12个月的Gemelli 1试验结果

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

著录项

引文网络

相似文献

相关主题

期刊订阅